{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cream+Vehicle&page=2", "query": { "intervention": "Cream Vehicle", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cream+Vehicle&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T22:36:37.348Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04211389", "title": "Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "ARQ-151 0.3% cream", "type": "DRUG" }, { "name": "ARQ-151 vehicle cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcutis Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 442, "start_date": "2019-12-17", "completion_date": "2020-11-23", "has_results": true, "last_update_posted_date": "2022-12-07", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 31, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Encino, California + 26 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04211389" }, { "nct_id": "NCT05078827", "title": "Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Actinic Keratoses" ], "interventions": [ { "name": "Test Product (A): Fluorouracil Cream, 5% topical cream", "type": "DRUG" }, { "name": "Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.", "type": "DRUG" }, { "name": "Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Encube Ethicals Pvt. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 458, "start_date": "2022-03-01", "completion_date": "2022-12-01", "has_results": false, "last_update_posted_date": "2023-03-14", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 7, "location_summary": "Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Lauderdale Lakes", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05078827" }, { "nct_id": "NCT02886702", "title": "A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Tazarotene Cream 0.05%", "type": "DRUG" }, { "name": "TAZORAC® (tazarotene) Cream 0.05%", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fougera Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 855, "start_date": "2016-09-19", "completion_date": "2017-08-02", "has_results": true, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02886702" }, { "nct_id": "NCT03727074", "title": "Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Actinic Keratosis (AK)" ], "interventions": [ { "name": "5-FU Cream", "type": "DRUG" }, { "name": "Efudex®", "type": "DRUG" }, { "name": "Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sol-Gel Technologies, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 462, "start_date": "2018-12-21", "completion_date": "2019-12-19", "has_results": false, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 1, "location_summary": "Cerritos, California", "locations": [ { "city": "Cerritos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03727074" }, { "nct_id": "NCT03173547", "title": "A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ichthyosis Vulgaris" ], "interventions": [ { "name": "146-9251 cream", "type": "DRUG" }, { "name": "Vehicle cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crown Laboratories, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 80, "start_date": "2017-04-25", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2021-08-10", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 7, "location_summary": "San Diego, California • Plainfield, Indiana • Metairie, Louisiana + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Plainfield", "state": "Indiana" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Fridley", "state": "Minnesota" }, { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03173547" }, { "nct_id": "NCT02661958", "title": "Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "S6G5T-3", "type": "DRUG" }, { "name": "S6G5T-1", "type": "DRUG" }, { "name": "S6G5T-5", "type": "DRUG" }, { "name": "S6G5T-6", "type": "DRUG" }, { "name": "S6G5T-7", "type": "DRUG" }, { "name": "S6G5T-8", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sol-Gel Technologies, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": null, "sex": "ALL", "summary": "9 Years and older" }, "enrollment_count": 726, "start_date": "2016-05", "completion_date": "2017-10", "has_results": false, "last_update_posted_date": "2019-09-19", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 34, "location_summary": "Anaheim, California • Cerritos, California • Chula Vista, California + 27 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02661958" }, { "nct_id": "NCT03958955", "title": "Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Discoid Lupus Erythematosus" ], "interventions": [ { "name": "Delgocitinib cream", "type": "DRUG" }, { "name": "Delgocitinib cream vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 27, "start_date": "2019-07-09", "completion_date": "2020-04-30", "has_results": true, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 5, "location_summary": "San Diego, California • Skokie, Illinois • Boston, Massachusetts + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Forest Hills", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03958955" }, { "nct_id": "NCT02132117", "title": "Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Erythema", "Rosacea" ], "interventions": [ { "name": "Oxymetazoline HCL Cream 1.0%", "type": "DRUG" }, { "name": "Vehicle to Oxymetazoline HCL Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 445, "start_date": "2014-06", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 1, "location_summary": "College Station, Texas", "locations": [ { "city": "College Station", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02132117" }, { "nct_id": "NCT01068158", "title": "A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head Lice" ], "interventions": [ { "name": "0.5% Ivermectin Cream", "type": "DRUG" }, { "name": "Placebo control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Topaz Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Months", "maximum_age": null, "sex": "ALL", "summary": "5 Months and older" }, "enrollment_count": 371, "start_date": "2010-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2012-04-06", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • Delray Beach, Florida • St. Petersburg, Florida + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Clyde", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01068158" }, { "nct_id": "NCT01502020", "title": "A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Actinic Keratoses" ], "interventions": [ { "name": "imiquimod cream, 3.75%", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Mid-Atlantic LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2011-02", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2011-12-30", "last_synced_at": "2026-09-22T22:36:37.348Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" }, { "city": "Arlington Heights", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01502020" } ] }